{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:51:20Z","timestamp":1770508280959,"version":"3.49.0"},"reference-count":64,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2003,9]]},"DOI":"10.1586\/14787210.1.3.423","type":"journal-article","created":{"date-parts":[[2005,1,13]],"date-time":"2005-01-13T08:42:24Z","timestamp":1105605744000},"page":"423-431","source":"Crossref","is-referenced-by-count":8,"title":["Peginterferon-\u03b1\n                    <sub>2a<\/sub>\n                    (40 kDa)\/ribavirin combination for the treatment of chronic hepatitis C infection"],"prefix":"10.1586","volume":"1","author":[{"given":"Wolfgang","family":"Vogel","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Innsbruck University, Austria. wolfgang.vogel@uibk.ac.at"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"e_1_2_1_5_1","doi-asserted-by":"crossref","unstructured":"Alter MJ. Epidemiology of hepatitis C. Hepatology26(Suppl. 1) 62\u201365 (1997).","DOI":"10.1002\/hep.510260711"},{"key":"e_1_2_1_6_1","first-page":"341","article-title":"Hepatitis C: global prevalence","volume":"72","author":"WHO","year":"1997","unstructured":"WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec. 72, 341\u2013344 (1997).","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07642-8"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)05413-5"},{"key":"e_1_2_1_9_1","doi-asserted-by":"crossref","unstructured":"Kim WR. The burden of hepatiiis C in the United States. Hpatology36 S30-S34 (2002).","DOI":"10.1053\/jhep.2002.36791"},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","unstructured":"Seeff LB. Natural history of chronic hepatitis C. Hepatology36 S35-S46 (2002).","DOI":"10.1053\/jhep.2002.36806"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92735-8"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198612183152503"},{"key":"e_1_2_1_13_1","unstructured":"\u2022This study was the first to show the principle of interferon OM treatment for chronic hepatitis C."},{"key":"e_1_2_1_14_1","doi-asserted-by":"crossref","unstructured":"National Institute of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology26 2S-10S (1997).","DOI":"10.1002\/hep.510260701"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701303360507"},{"issue":"1143","key":"e_1_2_1_16_1","article-title":"[Erratum","volume":"334","author":"Poynard T","year":"1995","unstructured":"Poynard T, Bedossa P, Chevalier M, et al. A comparison of three interferon-a2b regimens for the long-term treatment of chronic hepatitis non-A, non-B. N Engl.. 1. Med. 332,1457-1462 (1995) [Erratum N Engl. I Med. 334,1143 (1996)].","journal-title":"N Engl. I Med"},{"key":"e_1_2_1_17_1","doi-asserted-by":"crossref","unstructured":"Lindsay K Trepo C Heintges T et al. A randomized double-blind trial comparing pegylated interferon to interferon-a2b as initial treatment for chronic hepatitis C. Hepatology34 395\u2013403 (2001).","DOI":"10.1053\/jhep.2001.26371"},{"key":"e_1_2_1_18_1","unstructured":"\u2022This study was the first to evaluate the clinical efficacy of pegylated (PEG)-IFN-a2b."},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012073432301"},{"key":"e_1_2_1_20_1","unstructured":"\u2022A pivotal study to show the superiority of PEG-IFN-a2a."},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012073432302"},{"key":"e_1_2_1_22_1","doi-asserted-by":"crossref","unstructured":"Manns MP McHutchison JG Gordon SC et al. Peginterferon-a2 b plus ribavirin compared with interferon-a2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 958\u2013965 (2001).","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_1_23_1","unstructured":"\u2022A pivotal study to show the superiority of PEG-IFN-a2b ribavirin combination therapy over standard combination therapy."},{"key":"e_1_2_1_24_1","doi-asserted-by":"crossref","unstructured":"Fried MW Shiffman ML Reddy RK et al. Peginterferon a-2a (40 KD) in combination with ribavirin: efficacy and safety results from a Phase III randomized actively controlled multicenter study. N Engl. I. 114ed. 347 975\u2013982 (2002).","DOI":"10.1016\/S0016-5085(01)80271-7"},{"key":"e_1_2_1_25_1","unstructured":"\u2022A pivotal study to show the superiority of PEG-IFNa2a ribavirin combination therapy over standard combination therapy"},{"issue":"1","key":"e_1_2_1_26_1","volume":"36","author":"Hadziyannis SJ","year":"2002","unstructured":"Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon a-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a Phase III, randomized, double-blind multicentre study examining effect of duration of treatment and RBV dose. Hepatol 36\\(Suppl. 1), 3 (2002).","journal-title":"Hepatol"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.6.1139"},{"key":"e_1_2_1_28_1","author":"Rodriguez PJ","year":"1987","unstructured":"Rodriguez PJ, Parrot RII. Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants. Infect. Dis. N. A117. 1,525-539 (1987).","journal-title":"Infect. Dis. N"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(96)80225-X"},{"key":"e_1_2_1_30_1","doi-asserted-by":"crossref","unstructured":"Di Bisceglie AM Shindo M Fong T-L et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology16 649\u2013654 (1992).","DOI":"10.1002\/hep.1840160307"},{"key":"e_1_2_1_31_1","unstructured":"\u2022The first study to show the principle of ribavirin therapy for chronic hepatitis C."},{"key":"e_1_2_1_32_1","doi-asserted-by":"crossref","unstructured":"Bodenheimer HC Jr Lindsay KL Davis GL Lewis JH Thung SN Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology26 473-477 (1997).","DOI":"10.1002\/hep.510260231"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890460110"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80103-1"},{"key":"e_1_2_1_35_1","doi-asserted-by":"crossref","unstructured":"Reichard O Norkrans G Fryden A Braconier JH Sonnerborg A Weiland O. Randomised double-blind placebo-controlled trial of interferon-a2b with and without ribavirin for chronic hepatitis C. Lancet351 83\u201387 (1998).","DOI":"10.1016\/S0140-6736(97)06088-1"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198601023140104"},{"key":"e_1_2_1_37_1","volume":"1003775","author":"Najera I","year":"2001","unstructured":"Najera I, Laxton C, et al. Studies on inhibition of HCV replicon by ribavirin and possible mechanisms of action. Res. Report 1003775. February 26 (2001).","journal-title":"Res. Report"},{"key":"e_1_2_1_38_1","volume":"1003810","author":"Hartley J","year":"2001","unstructured":"Hartley J, Austin A. Inhibition of PHA-induced T-cell proliferation by ribavirin. Res. Report 1003810. March 1(2001).","journal-title":"Res. Report"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80093-2"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.4.541"},{"issue":"1","key":"e_1_2_1_41_1","first-page":"17","author":"Glue P","year":"1999","unstructured":"Glue P. The clinical pharmacology of ribavirin. Semin. Liver Disease. 19\\(Suppl. 1), 17\u201324 (1999).","journal-title":"Semin. Liver Disease"},{"key":"e_1_2_1_42_1","unstructured":"\u2022Important overview over ribavirin pharmacology."},{"key":"e_1_2_1_43_1","unstructured":"Davanaboyina US 26-week oral gavage toxicity and toxicokinetic study with a 6-week recovery phase with Ro 20-9963\/000 in dogs (Covance Study No. 6131\u2013301 Roche Study No. 07321) RR 1003489. April 3 (2001)."},{"key":"e_1_2_1_44_1","unstructured":"Van Birgelen. APJM. Ro 20-9963\/000 (Ribavirin): 26 week gavage oncogenicity study with Ro 20-9963\/000 (Ribavirin) in p53 plus or minus C57\/BL6 Mice (Covance Study No. 6131\u2013297 Roche Study No. 07402) RR 1003486. July 16 (2001)."},{"key":"e_1_2_1_45_1","first-page":"563","article-title":"Effect on ribavirin on zidovudine efficacy and toxicity in vitt-a assessment of possible pharmacokinetic and pharmacodynamic interactions. BE I","volume":"46","author":"Sim SM","year":"1998","unstructured":"Sim SM, Hoggard PG, Sales SD, etal. Effect on ribavirin on zidovudine efficacy and toxicity in vitt-a assessment of possible pharmacokinetic and pharmacodynamic interactions. BE I Gun. Pharmacol 46, 563\u2013570 (1998).","journal-title":"Gun. Pharmacol"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03618-7"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91707-2"},{"key":"e_1_2_1_48_1","unstructured":"\u2022Historic investigation on ribavirin for chronic hepatitis C."},{"key":"e_1_2_1_49_1","first-page":"48","article-title":"Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. I","volume":"8","author":"Thevenot T","year":"1999","unstructured":"Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. I Vital Hepat. 8, 48\u201362 (1999).","journal-title":"Vital Hepat"},{"key":"e_1_2_1_50_1","doi-asserted-by":"crossref","unstructured":"Schalm SW Fattovich G Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepato1ogy26(Suppl. 1) S128-S132 (1997).","DOI":"10.1002\/hep.510260722"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392102"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_1_53_1","doi-asserted-by":"crossref","unstructured":"Ferenci P Brunner H Nachbaur K et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology34 1006\u20131011 (2001).","DOI":"10.1053\/jhep.2001.28706"},{"key":"e_1_2_1_54_1","doi-asserted-by":"crossref","unstructured":"Berg T Hoffmann RM Teuber G et al. Efficacy of a short-term ribavirin plus interferon-a combination therapy followed by interferon-a alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. Liver20 427\u2013436 (2000).","DOI":"10.1034\/j.1600-0676.2000.020006427.x"},{"key":"e_1_2_1_55_1","first-page":"472","article-title":"Combination treatment of interferon-a2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients","volume":"31","author":"el-Zayadi A","year":"1999","unstructured":"el-Zayadi A, Selim O, Haddad S, Simmonds P, Hamdy H, Badran HM, Shawky S. Combination treatment of interferon-a2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital. Gastroenterol Hepatol 31,472\u2013475 (1999).","journal-title":"Ital. Gastroenterol Hepatol"},{"key":"e_1_2_1_56_1","doi-asserted-by":"crossref","unstructured":"Cummings KJ Lee SM West ES etal. Interferon and ribavirin vs. interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JA11\/14 285 193-199 (2001).","DOI":"10.1001\/jama.285.2.193"},{"key":"e_1_2_1_57_1","doi-asserted-by":"crossref","unstructured":"Kjaergard LL Krogsgaard K Gluud C. Interferon a with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BE Merl 1. 323 1151\u20131155 (2001).","DOI":"10.1136\/bmj.323.7322.1151"},{"key":"e_1_2_1_58_1","unstructured":"\u2022Important meta-analysis of the Cochrane Study Group."},{"key":"e_1_2_1_59_1","unstructured":"Ferenci P Shiffman ML Fried MW et al. Early prediction of response to 40KDA peginterferon-a2a (PEGASYS) plus ribavirin in patients with chronic hepatitisC. Hepatology34 351A (2001)."},{"key":"e_1_2_1_60_1","doi-asserted-by":"crossref","unstructured":"Reddy KR Wright TL Pockros PJ et al. Efficacy and safety of pegylated (40-kd) interferon-a2a compared with interferon-a2a in noncirrhotic patients with chronic hepatitis C. Hepatology33 433\u2013438 (2001).","DOI":"10.1053\/jhep.2001.21747"},{"key":"e_1_2_1_61_1","doi-asserted-by":"crossref","unstructured":"McHutchison JG Manns MP Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroentemlogy123 1061-1069 (2002).","DOI":"10.1053\/gast.2002.35950"},{"key":"e_1_2_1_62_1","doi-asserted-by":"crossref","unstructured":"Russo MW Fried MW. Side effects of therapy for chronic hepatitis C. Gastroentemlogy124 1711-1719 (2003).","DOI":"10.1016\/S0016-5085(03)00394-9"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.5789"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00029-0"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34175"},{"key":"e_1_2_1_66_1","unstructured":"Dieterich DT Pockros P Schiff ER et al. Interim results of a randomized double-blind placebo-controlled study demonstrates that epoietin-a (PROCRIT) allows maintenance of ribavirin dosing. Hepatology493 (2002) (Abstract)."},{"key":"e_1_2_1_67_1","doi-asserted-by":"crossref","unstructured":"Di Bisceglie AM Hoofnagle JH. Optimal Therapy of Hepatitis C. Hepatology36 S121-S127 (2002).","DOI":"10.1053\/jhep.2002.36228"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.3.425"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14787210.1.3.423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:02:41Z","timestamp":1770415361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14787210.1.3.423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["10.1586\/14787210.1.3.423"],"URL":"https:\/\/doi.org\/10.1586\/14787210.1.3.423","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}